Product Program year 2025 Source: CMS Open Payments

Spravato

Drug Neuroscience

NDC 50458-028-02

Open in the dashboard

General payments

$30,166,669

244,046 payments

Research payments

$19,756,147

1,304 payments

Through program year 2025, $30,166,669 in general payments and $19,756,147 in research payments were reported against Spravato (Neuroscience).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

13 rows
Year Kind Amount Payments
2025 General $6,220,899 44,546
2025 Research $2,266 1
2024 General $6,150,276 47,150
2024 Research $1,868,482 222
2023 General $5,738,303 48,352
2023 Research $8,085,808 549
2022 General $4,205,300 37,806
2022 Research $8,345,498 512
2021 General $2,201,152 26,440
2021 Research $1,029,654 13
2020 General $1,136,298 10,120
2020 Research $424,439 7
2019 General $4,514,441 29,632

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $27,591,450 242,035 payments
  2. Janssen Scientific Affairs, LLC $2,233,591 1,646 payments
  3. Janssen Research & Development, LLC $202,675 95 payments
  4. Janssen Global Services, LLC $116,348 170 payments
  5. Johnson & Johnson Health Care Systems Inc. $22,087 72 payments
  6. Janssen Biotech, Inc. $500 27 payments
  7. Johnson & Johnson Surgical Vision, Inc. $17 1 payment
Top recipients General payments · program year 2025
  1. Denver Health Medical Center Teaching hospital · CO $910,771 15% · 5 payments
  2. Helen Farrell Psychiatry · Cincinnati, OH $129,819 2% · 134 payments
  3. Kenny Perez Psychiatry · Miami, FL $125,501 2% · 155 payments
  4. Brittany Albright Psychiatry · Mount Pleasant, SC $121,160 2% · 181 payments
  5. Jay Fawver Psychiatry · Angola, IN $117,308 2% · 109 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Psychiatry Psychiatry & Neurology $2,955,671 56% · 2,572 practitioners
  2. Nurse Practitioner, Psychiatric/Mental Health Nurse Practitioner $1,175,507 22% · 5,639 practitioners
  3. Physician Assistant $286,094 5% · 1,507 practitioners
  4. Family Medicine $180,718 3% · 1,734 practitioners
  5. Child & Adolescent Psychiatry Psychiatry & Neurology $153,147 3% · 271 practitioners

The top 5 of 141 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Colorado $949,875 15% · 199 recipients
  2. Texas $587,499 9% · 1,489 recipients
  3. Florida $435,783 7% · 1,246 recipients
  4. California $328,500 5% · 1,114 recipients
  5. Illinois $298,802 5% · 1,009 recipients

The top 5 of 54 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

80,669

Prescriptions dispensed, refills included

Drug cost

$120,604,477

Paid at the pharmacy, in all

Prescribers

1,264

With 11 or more claims of it

Medicare Part D drugs matched to SPRAVATO, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Spravato Esketamine Hcl Same name 1,264 80,669 $120,604,477

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Marlon Quinones Psychiatry TX 1,549 $1,931,277 $286
Pamela Ruppel Nurse Practitioner VA 819 $1,207,334 $116
Julie Zito Physician Assistant CT 727 $933,536 $164
Padma Aking Psychiatry AZ 716 $1,305,493 $15,441
Troy Pulas Psychiatry FL 611 $780,247 $134

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
244,046 general · 1,304 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record